The abstract is read at the publisher; the summary is JClub's.
GLP-1 receptor agonists are linked to meaningful improvements in antipsychotic-associated weight gain and cardiometabolic outcomes in people with psychotic disorders, while consistent symptom benefits are not yet shown.
- Why it matters: People with psychotic disorders face a substantial cardiometabolic burden, and current treatments often worsen metabolic health; evidence is needed to connect metabolic mechanisms to clinical outcomes.
- What they did: A systematic review of clinical literature through March 7, 2026 synthesized preclinical and translational findings and narrative evidence from randomized trials, focusing on metabolic, inflammatory, redox, mitochondrial, gut-brain, and reward-related pathways.
- The result: Most randomized trials reported improvements in body weight and metabolic outcomes, but studies have not yet demonstrated consistent gains in psychotic symptoms, cognition, or functioning; effects on alcohol and nicotine use remain suggestive but inconclusive.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.